Introduction {#S0001}
============

*Helicobacter pylori* (*H. pylori*) seroprevalence varies significantly between different populations in the USA as well as worldwide \[[1](#CIT0001)--[3](#CIT0003)\]. *H. pylori* is considered a group 1 carcinogen by the World Health Organization and populations with high *H. pylori* infection rates tend to have a higher risk for gastric cancer \[[4](#CIT0004)\]. *H. pylori* infection typically progresses from gastritis and inflammation, to ulcers and eventually gastric cancer \[[5](#CIT0005)\]. While *H. pylori* is found in over 50% of the world's population \[[6](#CIT0006)\], not all infected will go on to develop secondary pathologic changes.

Multiple factors have been identified that account for the virulence of particular *H. pylori* strains, of which, the *cag* pathogenicity island (*cagPAI*) is the best characterised. The *cagPAI* encodes a secretory system that allows one of its gene products, CagA, to be injected into cells and affect cell function \[[7](#CIT0007)\]. Presence of the *cagPAI* has been found to be associated with more severe gastritis \[[7](#CIT0007)--[10](#CIT0010)\] and gastric cancer \[[11](#CIT0011),[12](#CIT0012)\].

Previous studies have found that up to 75% of the Alaska Native (AN) population are infected with *H. pylori*, and that AN people are between 2 and 4 times more likely to develop stomach cancer than the white US population \[[13](#CIT0013)--[16](#CIT0016)\]. Even after successful treatment and eradication, reinfection is frequent, especially among AN persons living in rural villages where a 2-year re-infection rate of 22% has been documented \[[17](#CIT0017)\]. These high rates of chronic infection likely contribute to disproportionately high rates of gastric cancer in AN people \[[14](#CIT0014),[18](#CIT0018),[19](#CIT0019)\].

In order to understand the underlying upper gastrointestinal (GI) pathology in AN people who present with significant chronic upper abdominal complaints, we reviewed endoscopic and pathologic results of AN adults who underwent endoscopic evaluation. We identified individuals who were *H. pylori* positive by pathology and evaluated the relationship between *H. pylori* and gastric pathology.

Methods {#S0002}
=======

Participant recruitment and evaluation was described previously \[[17](#CIT0017)\]. Briefly, Alaska Native adults (≥ 18 years) scheduled for esophagogastroduodenoscopy for clinical indications from 1998 through 2005 were recruited from clinical sites around Alaska. We analysed data participants recruited from the Alaska Native Medical Center in Anchorage and from the regional hospitals in Bethel, Dillingham, and Nome. Patients were excluded from the study if they had a history of gastric cancer, gastric resection, were pregnant or had undergone cancer chemotherapy or immunosuppressive therapy within the previous year. Information regarding *H. pylori* treatment and recent antibiotic and non-steroidal anti-inflammatory (NSAIDs) use was collected by chart review while information regarding tobacco and alcohol use was collected using a standard questionnaire.

Two gastric biopsies were collected for pathologic evaluation, one from the antrum and one from the fundus. These were processed and inoculated to solid media as described previously \[[17](#CIT0017),[20](#CIT0020)\]. Gastric biopsy tissue obtained at the time of esophagogastroduodenoscopy (EGD) were stained with Diff-Quik® (Mercedes Medical, USA) stain, for quantification of *H. pylori* and with haematoxylin and eosin stain for histological evaluation. Samples were considered positive for *H. pylori* if bacteria were observed on histologic examination. All biopsies were reviewed independently by two pathologists and graded using a tiered system. Pathologists were blinded to all other study results. Levels of acute gastritis were: None, Mild (rare clustered neutrophils), Moderate (neutrophils involved in several crypts), and Severe (multiple extensive crypt lesions in nearly every field). Levels of chronic gastritis were: None, Mild (lymphoplasmacytic infiltrates involving only the upper part of the mucosa), Moderate (lamina propria involved at all levels with expiation by lymphoplasmacytic infiltrates), and Severe (dense lymphoplasmacytic infiltrates at all levels with severe expansion or obliteration of epithelium). The levels of intestinal metaplasia (IM) were: None, Focal (rare or localised gland involvement), Patchy (several glands involved not in one focus), and Diffuse (most or all glands involved). The subjective concentration of *H. pylori* was graded using the following tiers: None, Focal (a few organisms found with difficulty), Moderate (multiple organisms in several areas), Numerous (organisms in nearly all areas). A sample was considered pathologic if at least one pathologist considered it to have pathologic changes.

During the EGD, gastric biopsy specimens were also collected for *H. pylori* culturing and genotyping, as previously described \[[21](#CIT0021),[22](#CIT0022)\]. PCR analysis was performed on *H. pylori* DNA extracts to detect the presence of the right and left ends of the *cagPAI*, as well as the *cagA, cagE, cagT*, and *virD4* genes (Supplemental Table 1). Due to potential sequence heterogeneity, two sets of primers were used for some genes. DNA extracts positive for all gene targets were considered to have originated from an *H. pylori* organism containing an intact *cagPAI*.

Anti-*H. pylori* IgG antibodies were measured using an enzyme-linked immunosorbent assay as described previously \[[23](#CIT0023)\]. As a *H. pylori* standard serum is not available, optical density (OD) is used as a surrogate for antibody titer. OD measurements were divided into "high" and "low" based on a threshold of 1.5. This threshold was chosen as it was 3 times greater than the cut-point for anti-HP positivity and approximated the 80^th^ percentile of the data distribution.

When combining results from the antral and fundal specimens and from the two pathologists, persons were considered to have *H. pylori*, gastritis or IM if it was found in ≥1 specimen or by ≥1 pathologist. The most severe grade was kept. Statistical analysis was performed by using StatXact 9 (Cytel Software Corp., USA) and SAS software v. 9 · 3 (SAS Institute Inc., USA). *p*-Values are two-sided and confidence limits and *p* values are exact when appropriate. Kappa statistic was used to determine inter-rater agreement. The following risk factor variables were analysed: age, sex, tobacco and alcohol use, study location, obesity (BMI ≥ 30), *H. pylori* concentration, elevated anti-HP antibodies, and presence of an intact *cagPAI* element. Univariate comparisons were made by use of the likelihood ratio chi-square test or the Cochran Armitage test of trend. Variables with a univariate *p*-value \<0.25 were considered in the multi-variable models. All variables were entered into the model and a backwards elimination with re-entry was used to select the final statistical model. Variables were considered confounders and remained in the model if their exclusion changed the value of the coefficient(s) of interest by \>15%. A *p*-value \< 0.05 was considered statistically significant.

The Institutional Review Boards of the Centers for Disease Control and Prevention and the Alaska Area Indian Health Service approved the study. In addition, the study was approved by the following Alaska Native tribal health organisations: Southcentral Foundation, Norton Sound Health Corporation, Yukon Kuskokwim Health Corporation, Bristol Bay Area Health Corporation, the Alaska Native Tribal Health Consortium Board of Directors. Written informed consent was obtained from all participants.

Results {#S0003}
=======

A total of 432 Alaska Native individuals participated in this study. Sixty-three per cent of participants were female and the mean age was 49 years ([Table 1](#T0001)). The most common reasons for endoscopy included stomach pain (84%), heartburn (71%), nausea (65%), or chronic symptoms including indigestion, reflux and epigastric pain (80%). Known risk factors for gastric pathology among participants included smoking (46%), any alcohol consumption (36%) and previous gastritis (47%) ([Table 1](#T0001)).10.1080/22423982.2018.1510715-T0001Table 1.General characteristics of *H. pylori* among Alaska native adults evaluated by esophagogastroduodenoscopy from 1998--2005.Demographics*N* (%)\
Total = 432% Female271 (63%)Rural Site121 (28%)Mean age49 years (range 18--88)Smoke200 (46%)Drink alcohol156 (36%)Previous gastritis205 (47%)

The most common endoscopic finding was gastritis (*n* = 358, 85%). Gastric ulcers were seen in 8% (*n* = 33) of patients and duodenal ulcers in 2% (*n* = 7). Ulcers were documented in the antrum \[*n* = 9, 22%\], duodenal bulb \[*n* = 7, 17%\], fundus \[*n* = 10, 25%\], the greater or lesser curvature of the stomach \[*n* = 3, 8%\], and at the pre pylorus or pylorus \[*n* = 11, 18%\]. Esophagitis was seen in 104 participants (24%).

Kappa statistics for agreement between pathologists for *H. pylori*, acute and chronic gastritis and IM are shown in [Table 2](#T0002). The two pathologists had good concordance on both presence/absence and grade of *H. pylori* and acute gastritis. The concordance was lower on chronic gastritis and the amount of IM.10.1080/22423982.2018.1510715-T0002Table 2.Kappa statistics for pathology between raters in the *H. pylori* study of Alaska native adults; 1998--2005.Pathology\
outcomeKappa statistic (95% confidence interval)Presence of *H. pylori*Amount Of\
*H. pylori*Presence and amount combined*H. Pylori*0.91 (0.87--0.95)0.72 (0.64--0.80)0.88 (0.85--0.91)Acute gastritis0.78 (0.72--0.84)0.63 (0.53--0.74)0.75 (0.70--0.80)Chronic gastritis0.65 (0.57--0.74)0.49 (0.41--0.57)0.64 (0.59--0.69)Intestinal metaplasia0.88 (0.80--0.95)0.35 (0.14--0.56)0.76 (0.68--0.84)

A total of 777 biopsies were obtained from 432 people of which 408 (53%) were from the antrum and 369 (47%) were from the fundus. 345 (80%) persons had two specimens (an antral and a fundal specimen), 24 (5%) had a fundal specimen only and 63 (15%) had an antral specimen only. Histological diagnoses are shown in [Table 3](#T0003). The overall prevalence of acute gastritis was 54% (*n* = 233) and chronic gastritis was 86% (*n* = 372). Fifty-one (12%) cases of IM were identified, two cases (0.5%) of gastric cancer and two cases (0.5%) of MALT lymphoma. Acute gastritis was more commonly detected in the antral (48%) than the fundal specimen (30%) and was more likely to be moderate--severe in the antral specimen (55%) than the fundal specimen (32%) (*p* \< 0.01 for both). The pattern was similar for chronic gastritis with chronic gastritis observed more often in the antral (83%) than fundal specimens (74%) and more likely to be moderate--severe in the antrum (*p* \< 0.01 for both). Similarly, IM was observed in 12% of antral specimens, but only 1% of fundal specimens (*p* \< 0.0001).10.1080/22423982.2018.1510715-T0003Table 3.Prevalence of histological diagnoses according to biopsy location; Alaska 1998--2005.Histological outcomeAntrum\
(*n* = 408)Fundus\
(*n* = 369)*p*-value\
(antrum vs. fundus)Antrum or fundus\
(*n* = 432)Acute gastritis48% (*n* = 194)30% (*n* = 109)\< 0.000154% (*n* = 233)Mild45%69%0.00446%Moderate48%28% 46%Severe7%4% 7%Chronic gastritis83% (*n* = 337)74% (*n* = 273)0.000186% (*n* = 372)Mild31%66% 33%Moderate55%29%\<0.000152%Severe14%5% 15%Intestinal metaplasia12% (*n* = 49)1% (*n* = 5)\<0.000112% (*n* = 51)Focal39%40%0.2239%Patchy59%40% 59%Diffuse2%20% 4%Gastric carcinoma0.5% (*n* = 2)0%Not tested0.5% (*n* = 2)MALT lymphoma0.5% (*n* = 2)0.3% (*n* = 1)Not tested0.5% (*n* = 2)*H. pylori* present54% (*n* = 220)54% (*n* = 199)0.4760% (*n* = 259)Focal20%32%\<0.000117%Moderate47%53% 47%Numerous33%16% 35%

Of 259 persons who were *H. pylori* positive based on pathologic exam, the *H. pylori* infection was classified as focal in 45 (17%), moderate in 123 (48%), and numerous in 91 (35%) ([Table 3](#T0003)). Two cases of gastric carcinoma and two cases of MALT lymphoma occurred; of these, one gastric carcinoma case and both of the MALT lymphoma cases were positive for *H. pylori*. Presence of *H. pylori* was similar between antrum and fundus with 54% of samples positive for *H. pylori* in both locations, however, *H. pylori* was more likely graded as numerous in the antral (*n* = 135, 33%) than the fundal specimen (*n* = 32, 16%, *p* \< 0.01). Among those people positive for *H. pylori*, 78% and 98% had acute and chronic gastritis respectively, compared to 18% and 69% of persons without *H. pylori* (when the mild, moderate and severe categories are combined, *p* \< 0.0001, [Table 4](#T0004)). When the prevalence of moderate--severe gastritis was compared between the *H. pylori* positive and negative participants, it was found that *H. pylori*-positive participants had 16 times the prevalence of moderate--severe acute gastritis (*p* \< 0.01) and 3.9 times the prevalence of moderate--severe chronic gastritis (*p* \< 0.01) when compared to *H. pylori*-negative participants ([Table 4](#T0004)). This elevated prevalence was found irrespective of the gastric location of the observed gastritis.10.1080/22423982.2018.1510715-T0004Table 4.Pathology of Alaska native adults positive and negative for *H. pylori*; 1998--2005.Characteristic*H. Pylori* statusPrevalence ratio\
(*95%*CI) ^a^Positive\
(*n* = 259)Negative\
(*n* = 173)% Female 59% (153)68% (118)0.87 (0.4, 1.0)Age ≥50 Years 41% (106)49% (85)0.83 (0.7, 1.0)Acute gastritis (fundal and antral combined)None22% (57)82% (142)refMild32% (82)15% (26)Moderate40% (104)2% (4)16.0 (6.7, 38.4) ^b^Severe6% (16)1% (1)FundusNone56% (124)91% (136)refMild29% (63)8% (12)Moderate13% (29)1% (1)22.3 (3.1, 161.6) ^b^Severe2% (4)0% (0)AntrumNone30% (73)88% (141)refMild29% (71)10% (16)Moderate37% (91)2% (3)16.8 (6.3, 44.7) ^b^Severe5% (12)1% (1)Chronic gastritis (fundal and antral combined)None2% (6)31% (54)refMild15% (39)47% (82)Moderate63% (162)19% (33)3.9 (2.9, 5.2) ^b^Severe20% (52)2% (4)FundusNone8% (18)52% (78)refMild53% (117)42% (63)Moderate34% (75)3% (5)7.2 (3.6, 14.4) ^b^Severe5% (10)2% (3)AntrumNone2% (6)40% (65)refMild16% (40)41% (66)Moderate63% (155)18% (29)4.4 (3.1, 6.1) ^b^Severe19% (46)1% (1)Intestinal metaplasia 13% (34)10% (17)1.3 (0.8, 2.3)Ulcer 9% (24)9% (16)1.0 (0.9, 1.1) Duodenal ulcer2% (6)1% (1)4.0 (0.5, 33.0) Gastric ulcer7% (18)9% (15)0.8 (0.4, 1.5)[^1][^2]

Among persons who were *H. pylori* positive, factors associated with acute and chronic gastritis and IM are shown in [Table 5](#T0005). An increasing concentration of *H. pylori* organisms identified in the biopsy specimen was positively correlated with the proportion of people who had moderate--severe acute and chronic gastritis; 60% and 90% of people who had numerous *H. pylori* on exam had moderate--severe acute and chronic gastritis, respectively. Similarly, moderate serve chronic gastritis was more common among persons with high levels of IgG antibody (79% vs. 93%, *p* \< 0.0001) ([Table 5](#T0005)).10.1080/22423982.2018.1510715-T0005Table 5.Factors associated with chronic (moderate/severe) and acute (moderate/severe) gastritis and intestinal metaplasia among Alaska native adults positive for *H. pylori* (*Hp*) by histological assessment; 1998--2005.FactorLevel (*n*)Acute gastritis\
(mod/sev)Chronic gastritis\
(mod/sev)Intestinal metaplasia% with (*n*)*p*-value% with (*n*)*p*-value% with (*n*)*p*-valueAge ≥50 YearsYes (*n* = 106)43% (46)0.4376% (81)0.03 ^d^22% (23)0.0007 ^d^No (*n* = 153)48% (74)87% (133)7% (11)SexF (*n* = 153)44% (67)0.3284% (129)0.3910% (16)0.13M (*n* = 106)50% (53)80% (85)17% (18)Study armUrban (*n* = 177)47% (84)0.5981% (143)0.2414% (24)0.76Rural (*n* = 82)44% (36)87% (71)12% (10)Obese (BMI ≥30Yes (*n* = 82)49% (40)0.5785% (70)0.4711% (9)0.47No (*n* = 147)45% (66)82% (120)14% (21)Alcohol use (any)Yes (*n* = 98)50% (49)0.3886% (84)0.3513% (13)0.86No (*n* = 160)44% (71)81% (130)13% (20)Current smoker ^a^Yes (*n* = 62)39% (24)0.1774% (46)0.05 ^d^15% (9)0.71No (*n* = 197)49% (96)85% (168)13% (25)Concentration of HPFocal (*n* = 45)18% (8)\< 0.0001 ^d^53% (24)\<0.0001 ^d^16% (7)0.85Moderate (*n* = 123)46% (57)88% (108)12% (15)Numerous (*n* = 91)60% (55)90% (82)13% (12)High anti-HP IgG ^c^Yes (*n* = 45)58% (26)0.0793% (42)0.014% (2)0.03No (*n* = 185)43% (79)79% (146)15% (28)Intact CAG^e^Yes (*n* = 120)62% (74)0.0002 ^d^88% (105)0.7916% (19)0.09 ^d^No (*n* = 97)36% (35)89% (86)8% (8)[^3][^4][^5][^6][^7]

Thirty-one people had evidence of acute gastritis but did not have any *H. pylori* detected by histology. Among *H. pylori*-negative individuals, persons with acute gastritis were more likely to be using proton pump inhibitors (*p* = 0.04) and less likely to be using H2 blockers (*p* = 0.02) than individuals who did not have signs of gastritis. Within this group, no association was found for reported alcohol, NSAID, antibiotic use or with previous *H. pylori* treatment (data not shown). No significant differences in exposures were found among the 119 *H. pylori*-negative individuals with chronic gastritis when compared to those without gastritis.

No differences were detected between persons with and without ulcers in terms of presence of *H. pylori* by histology ([Table 4](#T0004)), amount of *H. pylori* antibody at study entry (*p* = 0.72), presence and amount of acute gastritis (*p* = 0.56) or presence and amount of chronic gastritis (*p* = 0.43) (data not shown).

Of the 432 persons enrolled in the study, 217 were positive for *H. pylori* by culture. Of these, 129 (55%) of the Hp carried an intact *cagPAI* element (data not shown). Individuals with an intact *cagPAI* were more likely to have moderate to severe acute gastritis (*p* = 0.0002) when compared to persons without an intact cagPAI ([Table 5](#T0005)). When evaluated by gastric location, the trend remained for moderate--severe acute antral gastritis (*p* = 0.0003) but not fundal gastritis (*p* = 0.16) ([Figure 1](#F0001)). No relationship was seen between *cagPAI* integrity and chronic gastritis ([Table 4](#T0004)).10.1080/22423982.2018.1510715-F0001Figure 1.

On univariate and multivariable analysis, among persons positive for *H. pylori*, age greater than 50 years was associated with an decreased risk of moderate--severe chronic gastritis (*p* = 0.01) and increased risk of IM (*p* = 0.003). Presence of an intact *cagPAI* was associated with increased risk of IM (*p* = 0.047) and acute gastritis (*p* = 0.001). Increased *H. pylori* concentration on pathology was associated with increased acute gastritis (*p* = 0.047) and chronic gastritis (*p* \< 0.0001), while current smoking was associated with a decreased risk of chronic gastritis (*p* = 0.05) ([Table 5](#T0005)). No association was found between *H. pylori* concentration and gender, obesity or alcohol use.

Discussion {#S0004}
==========

Alaska Native persons have previously been shown to have a very high rate of *H. pylori* infection, ulcers, and gastric cancer \[[14](#CIT0014)--[16](#CIT0016)\]. This study characterised the distribution of *H. pylori* infection and characterised the pathologic changes found in Alaska Native patients who underwent upper endoscopy for gastric complaints. The high prevalence of inflammation found in this study is concerning as these types of lesions have a high risk of progressing to cancer.

Overall, 85% of participants had gastritis, 12% had IM, and 10% had ulcers. Both gastritis and IM were more common in the antrum than the fundus, while ulcers were seen five times more frequently in the body of the stomach compared to the duodenum. A high proportion of participants tested positive for *H. pylori* by histology, however this number cannot be considered reflective of the general population due to recruitment bias. *H. pylori*-positive participants were significantly more likely to have acute gastritis and chronic gastritis. In comparison to the gastric fundus, the antrum was more likely to have evidence of both acute and chronic gastritis and antral disease was more frequently categorised as severe. The antrum was more likely to have *H. pylori* present and the antrum was more likely to be infected with *H. pylori* with an intact *cagPAI* element. These observations are likely interrelated since specimens with more numerous *H. pylori* (higher concentration) were more likely to exhibit moderate to severe acute and chronic gastritis as well as IM.

Few studies have directly compared pathologist consistency in diagnosis of gastritis or *H. pylori* infection \[[24](#CIT0024)--[26](#CIT0026)\]. Here, specimens were reviewed by two pathologists independently, both as a way to validate the findings, but also to understand inter-pathologist variation. A high concordance was found between the two pathologists on the presence, absence, and concentration of *H. pylori*, the presence of IM, as well as the grade of acute gastritis, and a lower concordance was found between pathologists regarding chronic gastritis and grade of IM. This highlights the importance of including multiple evaluators in pathology studies.

Although *H. pylori* was found with equal frequency in the fundus and antrum, antral specimens were found to have a higher concentration of bacteria. In addition, antral specimens were more likely to have IM and the more severe forms of both acute and chronic gastritis. These results agree with previous work that have shown while the presence of *H. pylori* is equal in the body and fundus of affected individuals, the concentration of bacteria and the presence of disease is significantly greater in the antrum \[[27](#CIT0027)--[30](#CIT0030)\]. We found a direct correlation between the concentration of *H. pylori* in a specimen and the severity of both active and chronic gastritis. This finding was reinforced by the finding that the OD of *H. pylori* antibodies (a surrogate for concentration) correlated with both *H. pylori* concentration and gastritis severity. This finding supports earlier studies showing that the density of antibodies to *H. pylori* in blood correlates with the severity of antral gastritis and concentration of *H. pylori* found in the stomach \[[31](#CIT0031),[32](#CIT0032)\].

A few individuals had evidence of gastritis without any histologic evidence of *H. pylori* infection. These persons were more likely to use proton pump inhibitors and less likely to use a H~2~-receptor blocker when compared to persons who did not have gastritis. It is uncertain if these medications are affecting the *H. pylori* infection or reflect symptom severity and management. No association was seen between gastritis in those without *H. pylori* infection and NSAID use or alcohol consumption, known causes of gastritis. This is consistent with findings from an earlier case-series among Alaska Native persons in Anchorage which found evidence of gastritis in individuals in the absence of *H. pylori* infection or other known causes of gastritis \[[33](#CIT0033)\]. Whether these findings represent persistent mucosal changes after *H. pylori* infection or undetected infection is not known.

Previous work has suggested that the age of acquisition of *H. pylori* increases the likelihood that a person will develop cancer later in life \[[34](#CIT0034)--[36](#CIT0036)\]. It is thought that infection at an early age allows time for pathological progression through multiple stages, that ultimately result in gastric cancer \[[35](#CIT0035)\]. Gastric *H. pylori* infection initially causes inflammation which leads to destruction of parietal cells and results in a drop in stomach acidity. This change in acidity promotes further gastric infection and inflammation, while creating an unfavourable environment for *H. pylori* in the duodenum. Thus, populations in the early stages of infection are thought to have a low ratio of gastric to duodenal ulcers, while those in later stages have a high ratio. This information makes it possible to identify populations who are infected early in life, and at increased risk of cancer, as they have a higher ratio of gastric to duodenal ulcers. This study found a 4:1 ratio of gastric to duodenal ulcers. This ratio is similar to what was observed in earlier studies involving Alaska Natives and other Indigenous Arctic populations \[[33](#CIT0033),[37](#CIT0037),[38](#CIT0038)\], but the reverse of what is reported from the rest of the USA and many other populations around the world \[[39](#CIT0039)--[42](#CIT0042)\]. The high ratio of gastric ulcers is consistent with the idea that individuals in this population tend to acquired *H. pylori* infection at an early age and are at an increased risk of cancer \[[16](#CIT0016),[43](#CIT0043)\].

A significant association was found between infection with *H. pylori* with an intact *cagPAI* and both IM and moderate--severe acute antral gastritis. While the low number of cancers identified in this study makes it impossible to evaluate an association between genotype and cancer, it was possible to evaluate the association with intermediates in the cascade towards cancer. The progression from normal tissue to cancerous tissue is thought to be a change from acute gastritis to chronic gastritis to IM to cancer \[[44](#CIT0044),[45](#CIT0045)\]. The association seen here, between *cagPAI* and both IM and moderate--severe acute antral gastritis, agrees with previous reports that have shown an intact element is related to more severe disease \[[7](#CIT0007),[11](#CIT0011),[12](#CIT0012),[21](#CIT0021),[46](#CIT0046)--[48](#CIT0048)\]. A previous study in Alaska Native people found that over 90% of both individuals with gastric cancer and healthy individuals had antibodies against the CagA protein\[[19](#CIT0019)\], indicating that exposure to bacteria expressing and exporting this protein is very common. Here we show that while exposure to CagA expressing bacterial strains may be common, active infection with a strain carrying an intact element is less common and is associated with disease.

The multivariable analysis identified known risk factors for more severe disease, including older age, presence of an intact *cagPAI* and bacterial concentration in gastric biopsy specimens. One unexpected finding was an inverse association between current smoking and risk of moderate--severe chronic gastritis. Smoking is known to be associated with gastric cancer \[[49](#CIT0049),[50](#CIT0050)\]. The inverse relationship found here is likely due to a flaw in the questionnaire, which only asked about current smoking, not smoking history. This led to an underestimation of smoking exposure in the study population.

It is important to recognise that this study recruited symptomatic individuals, and therefore does not reflect the general population. The limited number of carcinoma and MALT cases made it impossible for any analysis of these outcomes. Ulcers were not found to be associated with *H. pylori* infection or gastritis, however very few ulcers were diagnosed as part of this study, thus limiting the ability to evaluate this outcome.

This study highlights the association between gastric lesion severity, the concentration of *H. pylori*, and the presence of cagPAI in Alaska Native people. It has previously been shown that Alaska Native people are at an increased risk for gastric cancer compared to the rest of the USA population \[[13](#CIT0013)--[16](#CIT0016)\]. While early screening for Alaska Native people for colorectal cancer secondary to the increased risk of this type of cancer in the Alaska Native population is recommended by the Alaska Native Medical Center \[[51](#CIT0051)\] no specific recommendations have been created for this population regarding gastric cancer. Given the gastric pathology observed in this study and the increased risk of gastric cancer among Alaska Native persons, it would be appropriate to consider whether a population-based screening approach for gastric cancer should be considered. Further studies are needed to evaluate screening and treatment methods for *H. pylori* and gastric cancer in this population.
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[^1]: ^a^Prevalence ratio represents the prevalence of the outcome in question in persons positive for *H. pylori* compared to those negative for *H. pylori.*

[^2]: ^b^Prevalence ratio for gastritis outcomes compares those with moderate or severe gastritis combined versus those with none or mild gastritis.

[^3]: ^a^ ≥10 cigarettes/day.

[^4]: ^b^ ≥20 delta over baseline.

[^5]: ^c^ OD ≥ 1.5.

[^6]: ^d^ Significant in multivariate model.

[^7]: ^e^*cagPAI.*
